Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 174

The DOI matches its Crossref record.

Effect of the early use of the anti–tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis

Bejarano, Victoria, Quinn, Mark, Conaghan, Philip G., Reece, Richard, Keenan, Anne‐Maree, Walker, David, Gough, Andrew, Green, Michael, McGonagle, Dennis, Adebajo, Ade, Jarrett, Stephen, Doherty, Sheelagh, Hordon, Lesley, Melsom, Richard, Unnebrink, Kristina, Kupper, Hartmut, Emery, Paul·2008·Arthritis Care & Research

Abstract

Objective: To compare work disability and job loss in early rheumatoid arthritis (RA) patients receiving adalimumab plus methotrexate (adalimumab + MTX) versus MTX alone. Methods: In this multicenter, randomized, controlled trial, patients with RA for <2 years who had never taken MTX and who self‐reported work impairment were randomized to adalimumab + MTX or placebo + MTX for 56 weeks. Primary outcome was job loss of any cause and/or imminent job loss at or after week 16. Secondary outcomes included disease activity, function (Health Assessment Questionnaire [HAQ] score), and RA quality of life (RAQoL) questionnaire score. Work was evaluated with work diaries and the RA Work Instability Scale. Results: Although job loss during the 56‐week study was significantly lower with adalimumab + MTX (14 of 75 patients) compared with MTX alone (29 of 73 patients; P = 0.005), the primary end point was not met (12 of 75 versus 20 of 73 patients; P = 0.092), likely owing to early drop out in the MTX group. There were significant improvements in American College of Rheumatology 20% response criteria, 28‐joint Disease Activity Score, ΔHAQ, ΔRAQoL, and working time lost in the adalimumab + MTX group. Twenty‐four serious adverse events were reported in 17 participants, with no differences between groups. Conclusion: Adalimumab + MTX reduced job loss and improved productivity in early RA when compared with MTX alone, which supports the early use of anti–tumor necrosis factor therapy and suggests its cost efficacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.24106

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 25

  1. 10.1136/ard.61.4.335 · DOI · Paper page
  2. 10.1002/art.20419 · DOI · Paper page
  3. 10.1002/art.21326 · DOI
  4. Backman CL, 2004, Participation in paid and unpaid work by adults with rheumatoid arthritis, J Rheumatol, 31, 47
  5. Guillemin F, 2004, Costs of rheumatoid arthritis in France: a multicenter study of 1109 patients managed by hospital‐based rheumatologists, J Rheumatol, 31, 1297
  6. 10.1056/NEJM200011303432201 · DOI · Paper page
  7. 10.1136/ard.2003.013961 · doi:10.1136/ard.2003.013961
  8. 10.1002/art.21405 · DOI · Paper page
  9. 10.1136/bmj.39265.679375.80 · doi:10.1136/bmj.39265.679375.80
  10. Quinn MA, 2001, Job loss increases in early RA despite control of disease activity: results from a large secondary care multi‐centre study using step‐up combination therapy, Arthritis Rheum, 44, S378
  11. 10.1002/art.11114 · DOI · Paper page
  12. 10.1136/ard.60.11.1025 · DOI
  13. Walker N, 2005, Work limitations among working persons with rheumatoid arthritis: results, reliability, and validity of the work limitations questionnaire in 836 patients, J Rheumatol, 32, 1006
  14. 10.1002/art.11285 · DOI
  15. 10.1002/art.21661 · doi:10.1002/art.21661
  16. 10.1002/art.1780310302 · DOI · Paper page
  17. 10.1002/art.1790050303 · DOI · Paper page
  18. De Jong Z, 1995, Development and validation of a RA‐specific quality of life measure (RAQoL), Arthritis Rheum, 38, S175
  19. 10.1093/rheumatology/40.10.1112 · DOI
  20. 10.1002/art.1780380107 · DOI · Paper page
  21. 10.1093/rheumatology/keh324 · doi:10.1093/rheumatology/keh324
  22. 10.7326/0003-4819-93-4-551 · DOI · Paper page
  23. 10.1002/art.20712 · DOI · Paper page
  24. 10.1002/art.20568 · DOI · Paper page
  25. 10.1002/art.21519 · DOI · Paper page

Cited by

See all 174

Metadata

Authors
Bejarano, V., Quinn, M., Conaghan, P. G., Reece, R., Keenan, A., Walker, D., Gough, A., Green, M., McGonagle, D., Adebajo, A., Jarrett, S., Doherty, S., Hordon, L., Melsom, R., Unnebrink, K., Kupper, H., & Emery, P.
Venue
Arthritis Care & Research
Publisher
Wiley
Published
2008-09-29
Volume
59
Issue
10
Pages
1467-1474
ISSN
  • 0893-7524 (ISSN-L)
  • 1529-0123
OpenAlex
W2072599775
Cited by
174
References
0
FWCI
12.35
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of the early use of the anti–tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. https://app.cochat.ai/papers/10.1002/art.24106
The paper
Bejarano, V., Quinn, M., Conaghan, P. G., Reece, R., Keenan, A., Walker, D., Gough, A., Green, M., McGonagle, D., Adebajo, A., Jarrett, S., Doherty, S., Hordon, L., Melsom, R., Unnebrink, K., Kupper, H., & Emery, P. (2008). Effect of the early use of the anti–tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Care & Research. https://doi.org/10.1002/art.24106

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.